Keros Therapeutics, Inc.
KROS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001664710
In the last 90 days, Keros Therapeutics, Inc. insiders filed 2 open-market purchases and 4 sales; 132 institutions reported holding it in 13F filings for Q2 2026, worth $198.6M in total; no superinvestor holds it.
13F holders, Q2 2022
Institutional positions in Keros Therapeutics, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 104
- −1 vs. Q1 2022
- Shares held
- 17.4M
- +936.9K (+5.7%) vs. Q1 2022
- Total value
- $479.7M
- −$413.2M (−46.3%) vs. Q1 2022
- New holders
- 20
- 43 more added
- Sold out
- 21
- 20 more reduced
1 institution that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KROS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 132 | $198.6M |
| Q1 2026 | 151 | $205.6M |
| Q4 2025 | 166 | $408.4M |
| Q3 2025 | 155 | $558.0M |
| Q2 2025 | 139 | $479.6M |
| Q1 2025 | 156 | $428.6M |
| Q4 2024 | 161 | $582.1M |
| Q3 2024 | 164 | $2.03B |
| Q2 2024 | 152 | $1.44B |
| Q1 2024 | 147 | $2.08B |
| Q4 2023 | 121 | $1.02B |
| Q3 2023 | 107 | $730.6M |
| Q2 2023 | 123 | $901.0M |
| Q1 2023 | 129 | $937.0M |
| Q4 2022 | 126 | $948.2M |
| Q3 2022 | 113 | $680.1M |
| Q2 2022 | 104 | $479.7M |
| Q1 2022 | 106 | $893.0M |
| Q4 2021 | 99 | $944.5M |
| Q3 2021 | 89 | $545.4M |
| Q2 2021 | 80 | $599.7M |
| Q1 2021 | 83 | $887.0M |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding Keros Therapeutics, Inc.; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| National Bank of Canada | 30 | $1.00K | 0.00% | 00.0% | Unchanged |
| Rockefeller Capital Management L.P. | 41 | $1.00K | 0.00% | +41 | New |
| Lindbrook Capital, LLC | 8 | $0 | 0.00% | −9−52.9% | Reduced |
| Covestor Ltd | 4 | $0 | 0.00% | −1−20.0% | Reduced |
| Woodline Partners LP | 0 | $0 | 0.00% | −257,200−100.0% | Sold out |
| Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD | 0 | $0 | 0.00% | −95,644−100.0% | Sold out |
| Integral Health Asset Management, LLC | 0 | $0 | 0.00% | −81,000−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −65,688−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −20,045−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −18,097−100.0% | Sold out |
| Handelsbanken Fonder AB | 0 | $0 | 0.00% | −7,400−100.0% | Sold out |
| Invesco Ltd. | 0 | $0 | 0.00% | −6,980−100.0% | Sold out |
| Manufacturers Life Insurance Company, The | 0 | $0 | 0.00% | −6,565−100.0% | Sold out |
| Voya Investment Management LLC | 0 | $0 | 0.00% | −6,131−100.0% | Sold out |
| ProShare Advisors LLC | 0 | $0 | 0.00% | −5,349−100.0% | Sold out |
| Price T Rowe Associates Inc | 0 | $0 | 0.00% | −4,505−100.0% | Sold out |
| Jasper Ridge Partners, L.P. | 0 | $0 | 0.00% | −4,042−100.0% | Sold out |
| Hyperion Capital Advisors LP | 0 | $0 | 0.00% | −4,042−100.0% | Sold out |
| BIT Capital GmbH | 0 | $0 | 0.00% | −1,700−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −1,237−100.0% | Sold out |
| Nisa Investment Advisors, LLC | 0 | $0 | 0.00% | −860−100.0% | Sold out |
| TCI Wealth Advisors, Inc. | 0 | $0 | 0.00% | −76−100.0% | Sold out |
| Parallel Advisors, LLC | 0 | $0 | 0.00% | −44−100.0% | Sold out |
| Signaturefd, LLC | 0 | $0 | 0.00% | −13−100.0% | Sold out |
| CWM, LLC | 0 | $0 | 0.00% | −8−100.0% | Sold out |
| Amalgamated Financial Corp. | – | – | – | – | Not filed |